Capital Advisors Ltd’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
Capital Advisors Ltd's ACRS Position: Q3 2026 in Review
Capital Advisors Ltd held its Aclaris Therapeutics (ACRS) position steady in Q3 2026 at 454 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1205.
Capital Advisors Ltd first reported a position in ACRS in Q2 2024 and has held it in 10 quarters since. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- Capital Advisors Ltd held 454 shares of Aclaris Therapeutics worth $2K as of Q3 2026.
- Capital Advisors Ltd left its Aclaris Therapeutics share count unchanged in Q3 2026.
- Aclaris Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q3 2026, its #1205 holding.
- Capital Advisors Ltd first reported a position in Aclaris Therapeutics in Q2 2024 and has held it in 10 quarters since.
- 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on Capital Advisors Ltd's 13F filing for Q3 2026, filed 27 Oct 2026.